How Many Endobains Are There?

Neurochemical Research

Volumn 25, Issue 9-10, 2000, Pages 1421-1430

  Rodríguez De Lores Arnaiz, Georgina ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Brain factors; Endobains; Endogenous factors; Na+, K+ ATPase inhibitors; Ouabain like factors; Sodium pump regulators

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; BIOLOGICAL FACTOR; DRUG DERIVATIVE; OUABAIN; POTASSIUM; SODIUM;

ANIMAL; BRAIN; CLASSIFICATION; HUMAN; METABOLISM; REVIEW;

ADENOSINE TRIPHOSPHATE; ANIMALS; BIOLOGICAL FACTORS; BRAIN; HUMANS; NA(+)-K(+)-EXCHANGING ATPASE; OUABAIN; POTASSIUM; SODIUM;

EID: 0034302894     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (116)

1. Albers, R. W. and Siegel, G. J. 1999. Membrane transport. Pages 95-118, in Siegel, G. J., Agranoff, B. W., Albers, R. W., Fisher, S. K., and Uhler, M. D., (eds.), Basic Neurochemistry, 6th edn., Lippincott-Raven, Philadelphia.
2. Skou, J. 1957. The influence of some cations on an adenosine triphosphatase from peripheral nerves. Biochem. Biophys. Acta 23:394-401.
3. +-ATPase of nervous tissue. Neurochem. Int. 8:449-476.
4. Kelly, R. A. and Smith, T. W. Pharmacological treatment of heart failure. 1996. Pages 809-838, in Hardman, J. G., and Limbird, L. E., (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn., McGraw-Hill, New York.
5. +-ATPaSe regulators. Mol. Neurobiol. 6:359-375.
6. Goto, A., Yamada, K., Yagi, N., Yoshioka, M., and Sugimoto, T. 1992. Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol. Rev. 44:377-399.
7. +-ATPase inhibitor purified from bovine adrenal. Biochem. Biophys. Res. Comm. 149:468-474.
8. Goto, A. and Yamada, K. 1998. Purification of endogenous digitalis-like factors from normal human urine. 1998. Clin Exp. Hypertens. 20:551-556.
9. Balzan, S., Ghione, S., Pieraccini, L., Biver, P., Di Bartolo, V., and Montali, U. 1994. Endogenous digitalis-like factor from umbilical cord and ouabain: comparison of biochemical properties. Pages 755-758, in Bamberg, E., and Schoner, W., (eds.), The Sodium Pump, Steinkopff, Darmstadt.
10. Martinka, E., Galajada, P., Ochodnicky, M., Lichardus, B., Straka, S., and Mokan, M. 1997. Endogenous digoxin-like immunoactivity and diabetes mellitus: facts and hypotheses. Med. Hypotheses 49:271-275.
11. Grider, G., El Mallakh, R. S., Huff, M. O., Buss, T. J., Miller, J., and Valdes, R. Jr. 1999. Endogenous digoxin-like immunoreactive factor (DLIF) serum concentrations are decreased in manic bipolar patients compared to normal controls. J. Affect. Disord. 54:261-267.
12. De Angelis, C., Riscazzi, M., Salvini, R., Piccoli, A., Ferri, C., and Santucci, A. 1997. Isolation and characterization of a digoxin-like immunoreactive substance from human urine by affinity chromatography. Clin. Chem. 43:1416-1420.
13. Bagrov, Y. Y., Dmitrieva, R. I., Manusova, N. B., Zvartau, E. E., Patkina, N. A., and Bagrov, A. Y. 1999. Involvement of endogenous digitalis-like factors in voluntary selection of alcohol by rats. Life Sci. 64:219-225.
14. Van Huysse, J. W. and Leenen, F. H. 1998. Role of endogenous brain "ouabain" in the sympathoexcitatory and presser effects of sodium. Clin. Exp. Hypertens. 20:657-667.
15. Budzikowski, A. S., Huang, B. S., and Leenen, F. H. 1998. Brain "ouabain", a neurosteroid, mediates sympathetic hyperactivity in salt-sensitive hypertension. Clin. Exp. Hypertens. 20:119-140.
16. +-ATPase inhibitors. Neurochem. Int. 27:319-327.
17. +-ATPase interaction with a brain endogenous inhibitor (endobain E). Neurochem. Int. 33:425-433.
18. Hamlyn, J. M., Lu, Z. R., Manunta, P., Ludens, J. H., Kimura, K., Shah, J. R., Laredo, J., Hamilton, J. P., Hamilton, M. J., and Hamilton, B. P. 1998. Observations on the nature, biosynthesis, secretion and significance of endogenous ouabain. Clin. Exp. Hypertens. 20:523-533.
19. Calderaro, V., Steffanini, R., Matera, M. G., Vacca, C., Dini, I., and Rossi, F. 1997. Physiological and pharmacological properties of an endogenous sodium pump inhibitor. Life Sci. 61:1457-1468.
20. Sancho, J. M. 1998. A non-ouabain Na / K ATPase inhibitor isolated from bovine hypothalamus. Its relation to hypothalamic ouabain. Clin. Exp. Hypertens. 20:535-542.
21. +-ATPaSe from midbrain and adrenal. Am. J. Physiol. 274:F182-188.
22. Kramer, H. J., Krampitz, G., Bäcker, A., and Meyer Lehnert, H. 1998. Ouabain-like factors in human urine: identification of a Na-K-ATPase inhibitor as vanadium-diascorbate adduct. Clin. Exp. Hypertens. 20:557-571.
23. Ferrandi, M., Manunta, P., Balzan, S., Hamlyn, J. M., Bianchi, G., and Ferrari, P. 1997. Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension 30:886-896.
24. Butt, A. N., Semra, Y. K., Ho, C. S., and Swaminathan, R. 1997. Effect of high salt intake on plasma and tissue concentration of endogenous ouabain-like substance in the rat. Life Sci. 61:2367-2373.
25. Pamnani, M. B., Swindall, B. T., Schooley, J. F., Ghai, R., and Haddy, F. J. 1999. Sodium-potassium pump inhibitor in the mechanism of one-kidney, one wrap hypertension in dogs. Cell Mol. Biol. 45:115-121.
26. Schneider, R., Wray, V., Nimtz, M., Lehmann, W. D., Kirch, U., Antolovic, R., and Schoner, W. 1998. Bovine adrenals contain, in addition to ouabain, a second inhibitor of the sodium pump. J. Biol. Chem. 273:784-792.
27. +. Neurochem. Res. 18:655-661.
28. +-ATPase inhibitors in plasma of healthy individuals and in dialysis dependent patients. Clin. Biochem. 22:313-319.
29. +-ATPase inhibitors in bovine plasma as fatty acids and hydrocarbons. Biochem. Biophys. Acta 985:55-59.
30. Cantley, L. C. Jr., Cantley, L. G., and Josephson, L. 1978. A characterization of vanadate interactions with the (Na,K)-ATPase. J. Biol. Chem. 253:7361-7368.
31. +-ATPaSe activity of synaptosomal membranes and whole homogenates prepared from rat cerebral cortex. Neurochem. Int. 11:11-16.
32. +)-ATPase. Biochem. Biophys. Res. Comm. 94:240-247.
33. Rodríguez de Lores Arnaiz, G. and Lopez Ordieres, M. G. 1997. A study of calcitonin effect on synaptosomal membrane enzymes. Peptides 18:613-615.
34. López Ordieres, M. G., Gironacci, M., Rodríguez de Lores Arnaiz, G., and Peña, C. 1998. Effect of angiotensin-(1-7) on ATPase activities in several tissues. Regulatory Peptides 77:135-139.
35. +-ATPase activity through high affinity peptide receptor. Peptides 21:571-576.
36. +-ATPase in nervous tissue. Pages 451-502, in Boulton, A. A., Baker, G. B., and Wu, P. H., (eds.), Neuromethods, Enzymes, Humana Press, Clifton, NJ.
37. +) adenosine triphosphatase of nerve ending membranes: action of norepinephrine and a soluble factor. Neurochem. Res. 3:733-744.
38. +-ATPase and its regulation by catecholamines. Pages 147-158, in Caputto, R., and Ajmone Marsand, C., (eds.), Neural Transmission, Learning and Memory, Raven Press, New York.
39. Fishman, M. C. 1979. Endogenous digitalis-like activity in mammalian brain. Proc. Natl. Acad. Sci. USA 76:4661-4663.
40. Lichtstein, D. and Samuelov, S. 1980. Endogenous ouabain like activity in rat brain. Biochem. Biophys. Res. Comm. 96:1518-1523.
41. +-ATPase and ouabain-binding in bovine central nervous system. J. Neurochem. 42:775-780.
42. Shimoni, Y., Gotsman, M., Deutsch, J., Kachalsky, S., and Lichtstein, D. 1984. Endogenous ouabain-like compound increases heart muscle contractility. Nature 307:369-371.
43. +-ATPase. Neurochem. Res. 11:933-947.
44. Haupert, G. T. and Sancho, J. M. 1979. Sodium transport inhibitor from bovine hypothalamus. Proc. Natl. Acad. Sci. USA 75:5735-5741.
45. Tymiak, A. A., Norman, J. A., Bolgar, M., Didonato, G. C., Lee, H., Parker, W. L., Lo, L. C., Berova, N., Nakanishi, K., Haber, E., and Haupert, G. T. Jr. 1993. Physicochemical characterization of a ouabain isomer isolated from bovine hypothalamus. Proc. Natl. Acad. Sci. USA 90:8189-8193.
46. Zhao, N., Lo, L., Berova, N., Nakanishi, K., Tymiak, A. A., Ludens, J., and Haupert, G. 1995. Na,K-ATPase inhibitors from bovine hypothalamus and human plasma are different from ouabain: Nanogram scale CD structural analysis. Biochemistry 34:9893-9896.
47. Lichtstein, D., Gati I., Samuelov S., Berson D., Rozenman Y., Landau L., and Deutsch, J. 1993. Identification of digitalis-like compounds in human cataractous lenses. Eur. J. Biochem. 216:261-268.
48. + pump in human cerebrospinal fluid. J. Neurophysiol. Sci. 90:217-230.
49. Lichtstein, D., Mine, D., Bourrit, A., Deutsch, J., Karlish, S. J. D., Belmaker, H., Rimon, R., and Palo, J. 1985. Evidence for the presence of "ouabain like" compound in human cerebrospinal fluid. Brain Res. 325:13-19.
50. Ludens, J. H., Clark., M. A., Ducharme, D. W., Harris, D. W., Lutske, B. S., Mandel, F., Mathews, W. R., Sutter, D. M., and Hamlyn, J. M. 1991. Purification fron human plasma of an endogenous digitalis-like factor for structural analysis. Hypertension 17:923-929.
51. Hamlyn, J. M., Harris, D. W., Clark, M. A., Rogowski, A. C., White, R. J., and Ludens, J. H. 1989. Isolation and characterization of a sodium pump inhibitor from human plasma. Hypertension 13:681-689.
52. Hamlyn, J. M., Blaustein, M. P., Bova, S., DuCharme, D. W., Harris, D. W., Mandel, F., Mathews, W. R., and Ludens, J. H. 1991. Identification and characterization of a ouabain-like compound from human plasma. Proc. Natl. Acad. Sci. USA 88:6259-6263.
53. Crambert, G., Balzan, S., Paci, A., Decollogne, S., Montali, U., Ghione, S., and Lelièvre, L. G. 1997. Functional characterization of an endogenous digitalis-like factor in human newborn plasma. Ann. NY Acad. Sci. 834:621-625.
54. Fedorova, O. V., Anderson, D. E., and Bagrov, A. Y. 1998. Plasma marinobufagenin-like and ouabain-like immunoreactivity in adrenocorticotropin-treated rats. Am. J. Hypertens. 11:796-802.
55. Mathews, W. R., DuCharme, D. W., Hamlyn, J. M., Harris, D. W., Mandel, F., Clark, M. A., and Ludens, J. H. 1991. Mass spectral characterization of an endogenous digitalis-like factor from human plasma. Hypertension 17:930-935.
56. +-ATPase inhibitor in patients after acute myocardial infarction. Hypertension 31:1097-1103.
57. Tao, Q. F., Hollenberg, N. K., Price, D. A., and Graves, S. W. 1997. Sodium pump isoform specificity for the digitalis-like factor isolated from human peritoneal dialysate. Hypertension 29:815-821.
58. +) ATPase associated with essential hypertension. Nature 300:650-652.
59. +-ATPase. Life Sci. 47:1091-1098.
60. +-ATPase inhibitor (endobain E) enhances norepinephrine release in rat hypothalamus. Neuroscience 90:573-579.
61. +-ATPase inhibitor on phosphoinositide hydrolysis in neonatal and adult rat brain cortex. J. Neurochem. 72 (Suppl.):S25B.
62. Di Bartolo, V., Balzan, S., Pieraccini, L., Ghione, S., Pegoraro, S., Biver, P., Revoltella, R., and Montali, U. 1995. Evidence for an endogenous ouabain-like immunoreactive factor in human plasma coeluted with ouabain on HPLC. Life Sci. 57:1417-1425.
63. Balzan, S., Montali, U., and Ghione, S. 1997. Evidence of an endogenous ouabain-like immunoreactive compound with digitalis-like properties in the human. Ann. NY Acad. Sci. 834:626-630.
64. +-ATPase modifiers on high-affinity ouabain binding determined by quantitative autoradiography. J. Neurosci. Res. 28:342-331.
65. Li, S., Eim, C., Kirch, U., Lang, R. E., and Schoner, W. 1998. Bovine adrenals and hypothalamus are a major source of proscillaridin A- and ouabain-immunoreactivities. Life Sci. 62:1023-1033.
66. Rodríguez de Lores Arnaiz, G., Alberici, M., and De Robertis, E. 1967. Ultrastructural and enzymic studies of cholinergic and non-cholinergic synaptic membranes isolated from brain cortex. J. Neurochem. 14:215-225.
67. +. Biochem. Biophys. Acta 171:178-185.
68. Rodríguez de Lores Arnaiz, G., Antonelli de Gómez de Lima, M., and Girardi, E. 1988. Different properties of two brain fractions separated in Sephadex G-50 that modify synaptosomal ATPase activities. Neurochem. Res. 3:229-235.
69. +-pump inhibitors isolated from bovine hypothalamus and hypophysis. FEBS Lett. 261:436-440.
70. +-ATPase inhibitor and ouabain. Neurochem. Res. 22:379-383.
71. +)-ATPase. Biochem. Biophys. Acta 429:993-1005.
72. +-adenosine triphosphatase. Effect of potassium. Biochem. Pharmacol. 38:3689-3695.
73. Goldstein, A., Goldstein, J. S., and Cox, B. M. 1975. A synthetic peptide with morphine-like pharmacologic action. Life Sci. 17:1643-1654.
74. +)-activated ATPase from ox brain. Biochem. Biophys. Acta 311:51-66.
75. +)-activated ATPase. A biochemical link to digitalis-induced inotropy. Pharmacol. Rev. 36:143-163.
76. +-ATPase inhibition by cardiac glycosides with fast and low binding kinetics. Eur. J. Pharmacol. 335:89-97.
77. +-ATPase as a possible mechanism for the potassium-induced reversal of their toxicity. Naunyn-Schmiedeberg' Arch. Pharmacol. 304:157-165.
78. +-ATPase. Eur. J. Pharmacol. 111:147-157.
79. +-ATPase-specific inhibitor from pig urine. Eur. J. Biochem. 211:317-327.
80. +-ATPase inhibition by a rat brain endogenous factor (endobain E). Neurochem. Res. 23:33-37.
81. +-ATPase inhibitor (endobain E). J. Neurochem. 70 (Suppl. 1): S60B.
82. Paton, W. D. M., Vizi, E. S., and Zar, M. A. 1971. The mechanism of acetylcholine release from parasympathetic nerves. J. Physiol. Lond. 215:819-848.
83. 2+)-activated ATPase, of acetylcholine release in cortical slices from rat brain. J. Physiol. Lond. 226:95-117.
84. +-activated adenosinetriphosphatase as a trigger in transmitter release. Neuroscience 3:367-384.
85. Birks, R. I. 1963. The role of sodium ions in the metabolism of acetylcholine. Can. J. Biochem. Physiol. 39:2573-2597.
86. Gaitonde, B. B. and Joglekar, S. N. 1977. Mechanism of neurotoxicity of cardiotonic glycosides. Br. J. Pharmac. Chemother. 59:223-229.
87. +-evoked catecholamine release in the cat adrenal gland treated with ouabain. Br. J. Pharmacol. 74:673-680.
88. Wakade, A. R. 1981. Facilitation of secretion of catecholamines from rat and guinea-pig adrenal glands in potassium-free medium or after ouabain. J. Physiol. (London) 313:481-498.
89. Pocock, G. 1983. Ion movements in isolated bovine adrenal medullary cells treated with ouabain. Mol. Pharmacol. 23: 681-697.
90. +-ATPase, its endogenous ligands and neurotransmitter release. Neurochem. Int. 20:11-17.
91. +-ATPase. Micr. Electr. Biol. Cell. 15:93-106.
92. Balduini, W. and Costa, L. G. 1990. Characterization of ouabain-induced phosphoinositide hydrolysis in brain slices of the neonatal rat. Neurochem. Res. 15:1023-1030.
93. +-ATPase inhibitor. J. Neurochem. 74 (Suppl.):S19D.
94. +-ATPase activity likewise modify muscarinic receptor. Neurochem. Res. 24:1417-1422.
95. 3H]MK-801 binding to NMDA receptor. J. Neurochem. 72 (Suppl.):S78D.
96. +-ATPase inhibitor. J. Neurochem. 74 (Suppl.):S65B.
97. Yamada, H. M., Naruse, M., Naruse, K., Demura, H., Takahashi, H., Yoshimura, M., and Ochi, J. 1992. Histological study on ouabain immunoreactivities in the mammalian hypothalamus. Neurosci. Lett. 141:143-146.
98. Ferrandi, M., Minotti, E., Salardi, S., Florio, M., Bianchi, G., and Ferrari, P. 1992. Ouabain-like factor in Milan hypertensive rats. Am. J. Physiol. 263:F739-F748.
99. Hamlyn, J. M. and Manunta, P. 1992. Ouabain, digitalis-like factors and hypertension. J. Hypertension 10(Suppl.):952-1178.
100. Antolovic, R., Kost, H., Mohadjerani, M., Linder, D., Linder, M., and Schoner, W. 1998. A specific binding protein for cardiac glycosides exists in bovine serum. J. Biol. Chem. 273: 16259-16264.
101. +-ATPase. Biochem. Biophys. Acta 988:185-220.
102. Berrebi-Bertrand, I., Maixent, J. M., Christe, G., and Leleièvre, L. G. 1990. Two active Na/K-ATPases of high affinity for ouabain in adult rat brain membranes. Biochem. Biophys. Acta 1021:148-156.
103. Blaustein, M. P., Juhaszova, M., and Golovina, V. A. 1998. The cellular mechanism of action of cardiotonic steroids: a new hypothesis. Clin Exp. Hypertens. 20:691-703.
104. +-pump in human mesenteric arteries. J. Hypertens. 16:1953-1958.
105. +-ATPase activity. Neurochem. Res. 15:289-294.
106. +-ATPase. J. Neurosci. 11: 381-391.
107. Calviño, M. A., Peña, C., and Rodríguez de Lores Arnaiz, G. 1998. Endogenous modulators of brain at early postnatal stages of rat development. Int. J. Devl. Neuroscience 16:97-102.
108. Kunes, J., Stolba, P., Pohlova, I., Jelinek, J., and Zicha, J. 1985. The importance of endogenous digoxin-like factors in rats with various forms of experimental hypertension. Clin. Exp. Hypert. A7:707.
109. Vizi, E. S., Oberfrank, F., Bernath, S., and Lichtstein, D. 1987. Noradrenaline releasing effect of an ouabain-like compound on pulmonary artery. Neuropharmacology 26:1541-1544.
110. Huang, B. S. and Leenen, F. H. H. 1995. Brain ouabain, sodium, and arterial baroreflex in spontaneous hypertensive rats. Hypertension 25 (part 2):814-817.
111. Leenen, F. H. H., Harmsen, E., Yu, H., and Ou, C. 1993. Effects of dietary sodium on central and peripheral ouabain-like activity in spontaneously hypertensive rats. Am. J. Physiol. 264:H2051-H2055.
112. Leenen, F. H. H., Harmsen, E., and Yu, H. 1994. Dietary sodium and central vs. peripheral ouabain-like activity in Dahl salt-sensitive vs. salt-resistant rats. Am. J. Physiol. 267:H1916-H1920.
113. Leenen, F. H. H., Huang, B. S., Yu, H., and Yuan, B. 1995. Brain "ouabain" mediates sympathetic hyperactivity in congestive heart failure. Circ. Res. 77:993-1000.
114. Reisine, T. and Pasternak, G. 1996. Opioid analgesics and antagonists. Pages 521-555, in Hardman, J. G., and Limbird, L. E., (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn., McGraw-Hill, New York.
115. Pertwee, R. G. 1999. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6:635-664.
116. Martin, B. R., Mechoulam, R., and Razdan, R. K. 1999. Discovery and characterization of endogenous cannabinoids. Life Sci. 65:573-595.